Compare FET & CADL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FET | CADL |
|---|---|---|
| Founded | 2005 | 1999 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Metal Fabrications | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 645.5M | 578.8M |
| IPO Year | 2007 | 2021 |
| Metric | FET | CADL |
|---|---|---|
| Price | $53.64 | $9.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $19.00 |
| AVG Volume (30 Days) | 124.3K | ★ 2.1M |
| Earning Date | 04-30-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 92.64 | 58.62 |
| EPS | ★ 0.39 | N/A |
| Revenue | ★ $791,474,000.00 | $125,000.00 |
| Revenue This Year | $7.35 | N/A |
| Revenue Next Year | $6.95 | N/A |
| P/E Ratio | $133.77 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $15.93 | $4.35 |
| 52 Week High | $65.43 | $9.27 |
| Indicator | FET | CADL |
|---|---|---|
| Relative Strength Index (RSI) | 44.20 | 73.20 |
| Support Level | $48.86 | $4.80 |
| Resistance Level | $63.59 | N/A |
| Average True Range (ATR) | 2.65 | 0.59 |
| MACD | -0.28 | 0.01 |
| Stochastic Oscillator | 45.66 | 89.29 |
Forum Energy Technologies Inc is a manufacturing company serving the oil, natural gas, industrial, and renewable energy industries. Its products include engineered capital equipment, as well as products that are consumed in the drilling, well construction, production, and transportation of oil and natural gas. The company operates in two reportable segments: Drilling and Completions, and Artificial Lift and Downhole. Maximum revenue is generated from the Drilling and Completions segment, which offers products used in the drilling process, and other products like hydraulic fracturing pumps, ROVs and trenchers, submarine rescue vehicles, etc. Geographically, the firm generates maximum revenue from the U.S., followed by Canada, Middle East, Europe and Africa, Asia-Pacific, and Latin America.
Candel Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. The immune cells induced by these viral immunotherapies are believed to target patients' specific tumor antigens, potentially improving responses in immunologically hot tumors while at the same time infiltrating the tumor microenvironment, transforming non-inflamed cold tumors with limited immune response into hot tumors. The company has established two clinical off-the-shelf viral immunotherapy platforms based on novel, genetically modified adenovirus and herpes simplex virus (HSV) constructs, respectively.